Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Capital Expenditures (2017 - 2025)

Catheter Precision (VTAK) has disclosed Capital Expenditures for 9 consecutive years, with $7000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Capital Expenditures fell 84.44% to $7000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $17000.0, a 80.0% decrease, with the full-year FY2024 number at $67000.0, down 11.84% from a year prior.
  • Capital Expenditures was $7000.0 for Q2 2025 at Catheter Precision, down from $10000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $89000.0 in Q2 2021 to a low of -$83000.0 in Q3 2021.
  • A 5-year average of $14923.1 and a median of $18000.0 in 2023 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 323.81% in 2021; the steepest drop was 460.87% in 2021.
  • Catheter Precision's Capital Expenditures stood at -$9000.0 in 2021, then skyrocketed by 288.89% to $17000.0 in 2022, then increased by 5.88% to $18000.0 in 2023, then soared by 150.0% to $45000.0 in 2024, then plummeted by 84.44% to $7000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Capital Expenditures are $7000.0 (Q2 2025), $10000.0 (Q1 2025), and $45000.0 (Q2 2024).